CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Practice Management

 

Why Does an MRI Cost $1,080 in the U.S. and $280 in France?

By James Doulgeris | March 11, 2012

The Washington Post’s Ezra Klein, in an article entitled “Why an MRI costs

,080 in the US and The Washington Post’s Ezra Klein, in an article entitled “Why an MRI costs $1,080 in the US and $280 in France,” correctly concludes the obvious: “The prices are higher.”

But what really drives these prices? Technology —from cotton balls and band aids to drugs to robotic surgical marvels — all of which represent the vast majority of our healthcare costs. They are the tools that our doctors, hospitals, and other clinicians use. Those tools, in skilled hands, have more than doubled our life spans at a vastly improved quality of life in a bit over a hundred years.

The real reason an MRI costs four times higher in the U.S. than it does in France is because we Americans bear the entire burden to invent it, develop it, make it safe, and pay if it proves not to be safe. France only pays for the product and protects its government-run system, doctors, and technicians from liability. Our doctors and hospitals are fully liable, and we bear that cost, too.

Klein accurately documents that the U.S. is far more expensive than its western counterparts, again properly citing that the single-payer, government-run systems negotiate aggressively to pay only for the product while U.S. providers, from doctors to drug companies, set their own prices. They set them high. And, the rest of the world owes us for it.

We need real and fundamental change and an honest public conversation to set things right. We need leaders with the kind of political will that takes courage, honesty, drive, and the integrity to fix fundamental problems. Our representatives, from the president to U.S. Congress, must step up because only they can enact and enforce the solution. And, they must do it now and start here with the big dollars:

1. Everyone must pay their share for innovation. Virtually the entire cost of medical and healthcare innovation for the world is recovered in high U.S. prices including the cost of all the products that don’t get to market. The rest of the world innovates, but only because they can recover their costs in the U.S. by building them into their price. Government controlled systems, from Argentina to Europe, pay only for the product. Join them and innovation stops — everywhere. They need to pony up.

80 in France,” correctly concludes the obvious: “The prices are higher.”

But what really drives these prices? Technology —from cotton balls and band aids to drugs to robotic surgical marvels — all of which represent the vast majority of our healthcare costs. They are the tools that our doctors, hospitals, and other clinicians use. Those tools, in skilled hands, have more than doubled our life spans at a vastly improved quality of life in a bit over a hundred years.

The real reason an MRI costs four times higher in the U.S. than it does in France is because we Americans bear the entire burden to invent it, develop it, make it safe, and pay if it proves not to be safe. France only pays for the product and protects its government-run system, doctors, and technicians from liability. Our doctors and hospitals are fully liable, and we bear that cost, too.

Klein accurately documents that the U.S. is far more expensive than its western counterparts, again properly citing that the single-payer, government-run systems negotiate aggressively to pay only for the product while U.S. providers, from doctors to drug companies, set their own prices. They set them high. And, the rest of the world owes us for it.

We need real and fundamental change and an honest public conversation to set things right. We need leaders with the kind of political will that takes courage, honesty, drive, and the integrity to fix fundamental problems. Our representatives, from the president to U.S. Congress, must step up because only they can enact and enforce the solution. And, they must do it now and start here with the big dollars:

1. Everyone must pay their share for innovation. Virtually the entire cost of medical and healthcare innovation for the world is recovered in high U.S. prices including the cost of all the products that don’t get to market. The rest of the world innovates, but only because they can recover their costs in the U.S. by building them into their price. Government controlled systems, from Argentina to Europe, pay only for the product. Join them and innovation stops — everywhere. They need to pony up.

2. Everyone must pay their share for product safety. Innovators bear the entire burden to satisfy regulators their innovations are safe. The costs begin in the millions and escalate into the billions for some drugs — pass or fail — and plenty fail never generating a dime in revenue. The costs are not only in the United States, but the right to sell in other countries requires paying to comply with their regulations. The U.S. bears virtually the entire cost including foreign regulatory compliance in high prices because, once again, government controlled systems pay only for the product.

(MORE: Managing Patient Expectations: Effective Communication)

3. Everyone must pay for the right of recourse. If a product proves to be harmful, even if only to a small percentage of people, the innovator pays to defend itself and, usually, plaintiffs costs. Plus damages. And government-run systems protect themselves by limiting liability to themselves and their providers, transferring liability to the innovators. They pay only for the product. We pay for the world’s right to be made whole in high prices.

Start here and we will have the resources to tackle the rest.

Make the beneficiaries of our innovation, regulation, and recourse pay their fair share.

Find out more about James Doulgeris and our other Practice Notes bloggers.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Charles Sisco | March 13, 2012 12:43 PM EDT

To paraphrase former President Bill Clinton, it depends upon what the word "cost" means. I propose the money paid by insurance companies and CMS for an MRI is pretty close to the $280 paid in France.

by Calvin Richardson | March 13, 2012 11:20 AM EDT

I have trouble agreeing with you on this topic but could be convinced if you clarify some of the more technical points. Namely, how should other users of such innovative technologies be cajoled into paying their fair share? If the technology is being sold for a fixed price to a certain single-payer system, could the pharma/biotech company simply hold out in negotiations until a higher price was reached? If a similar technology is being offered by another competitor, then shouldn't the single-payer be allowed to negotiate with both companies and take the lowest offer?

In my mind I keep coming back to why the U.S. pays so much as opposed to why other countries pay so little.

Read more from James Doulgeris

Health Literacy Needs a Place in Physicians' Practices

New Survey Validates That US Physicians are Ailing

How to Manage Patient Expectations Created by the Media

How Market Research Can Position Physician Practices to Succeed

How Physicians Can Negotiate the Best Hospital Employment Deal

How a Romney-Ryan Administration Could Affect Physicians

A Critical Assessment of the Affordable Care Act

How Businesses Can Help Stem the Physician Shortage

Managing Patient Referrals, Retention, and Risk the Disney Way

The Five Biggest Medical Practice Marketing Mistakes

Managing Patient Expectations: Access to Care

Managing Patient Expectations: Are Physicians Becoming Less Relevant?

Managing Patient Expectations: Helping Patients Pay Their Bills

Managing Patient Expectations: What Drives Outpatient Services

Managing Patient Expectations: Better Coordinated Care

Managing Patient Expectations: Personalized Medicine

Managing Patient Expectations: Practice Access and Responsiveness

Why Does an MRI Cost $1,080 in the U.S. and $280 in France?

Managing Patient Expectations: Providing Portable Medical Records

Managing Patient Expectations: Explaining the Reality of Medicine

Three Strategies to Help Patients with High-Deductible Health Plans

Time for Physicians to Take Care of Business (Part II)

Time for Physicians to Take Care of Business (Part I)

Top 10 Changes in Patient Expectations (Part II)

How the Pros Repair Damaged Physician Online Reputations

How the Pros Market Medical Practice Websites

US Healthcare Results: Sicker Patients, Ailing Economy

Surveys: Patients Coming, Physicians Leaving Due to ACA

Make Better Business Decisions at Your Medical Practice

If ACA Survives, Many Small Medical Practices Will Fail

Reform Driving Physicians Out of Private Practice to Reduce Costs

Five Strategies to Survive as a Physician Under the ACA

Top 10 Changes in Patient Expectations (Part I)

Valuation Strategies for Physicians' Practices

Physicians' Online Reputations Under Attack from Turned-away Drug Seekers

How the Popular Press Affects Patient Expectations

Physician Burnout Symptomatic of Healthcare's Current State

Managing Patient Expectations: Effective Communication






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Preventing Exposure to Hazardous Drugs
  • Conflicts of Interest in Medicine: What About Ties to Payers?
  • Planning Treatment for Women With Recurrent Epithelial Ovarian Cancer
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Practice Management
Evidence on Practice Management
Guidelines on Practice Management
Patient Education on Practice Management
Clinical Trials on Practice Management
Practical Articles on Practice Management
Research and Reviews on Practice Management
All "Practice Management" results

CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy